GFAP/UCH-L1 as a Biomarker for Rapid  Assessment of Mild TBI in Emergency Departments

11 June 2025 : Clinical Research

Rakesh Jalali

^{ABCDEFG 1,2*}, Marcin Bałuch

^{BCE 1,2}, Joanna Malinowska

^{BF 1,2}, Jacek Zwiernik

^{BF 3}, Adam Kern

^{BF 4}, Jacek Bil

^{BF 5}, Jerzy Romaszko

^{BF 6}

DOI: 10.12659/MSM.948353

Med Sci Monit 2025; 31:e948353

Authors information Article notes Copyright and License information

Introduction Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 3 Sensitivity and specificity of tests.

	Test	Sensitivity	Specificity
Overall	GFAP	83.3%	37.9%
	UCH-L1	50.0%	65.0%
	TBI	83.3%	29.1%
Neurological/psychiatric disorders	UCH-L1	100.0%	76.9%
Nephrological disorders	UCH-L1		25.0%
Metabolic disorders	GFAP	100.0%	18.0%
Metabolic disorders	TBI	100.0%	15.4%
Cardiovascular disorders	GFAP	100.0%	20.3%
	UCH-L1	66.7%	60.7%
	TBI	100.0%	18.0%
Bone injuries	UCH-L1	100.0%	45.5%
Spine injuries	TBI	100.0%	48.0%

Back to the Article